Erratum: Changing interactions between physician trainees and the pharmaceutical industry: A national survey (Journal of General Internal Medicine DOI: 10.1007/s11606-013-2361-0);Changing interactions between physician trainees and the pharmaceutical industry: A national survey

Journal of General Internal Medicine

Volumn 28, Issue 8, 2013, Pages 1064-1071

  Austad, Kirsten E ^a,b   Avorn, Jerry ^a   Franklin, Jessica M ^a   Kowal, Mary K ^a   Campbell, Eric G ^c   Kesselheim, Aaron S ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

conflict of interest; drug promotion; pharmaceutical industry; undergraduate medical education

Indexed keywords

ADULT; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DRUG INDUSTRY; FEMALE; FUNDING; HEALTH CARE POLICY; HUMAN; LEARNING ENVIRONMENT; MALE; MEAL; MEDICAL EDUCATION; MEDICAL PROFESSION; MEDICAL SCHOOL; MEDICAL STUDENT; NORMAL HUMAN; PHYSICIAN ATTITUDE; RESIDENT; REVIEW;

EID: 84880514582     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-013-2524-z     Document Type: Erratum

References (36)

1. Brody H. Pharmaceutical industry financial support for medical education: benefit, or undue influence? J Law Med Ethics. 2009;37(3):451-460.
2. Campbell EG, Regan S, Gruen RL, Ferris TG, Rao SR, Cleary PD, Blumenthal D. Professionalism in medicine: results of a national survey of physicians. Ann Intern Med. 2007;147(11):795-802.
3. Steinbrook R. Future directions in industry funding of continuing medical education. Arch Intern Med. 2011;171(3):257-258.
4. Avorn J, Choudhry NK. Funding for medical education: maintaining a healthy separation from industry. Circulation. 2010;121(20):2228-2234.
5. Campbell EG, Weissman JS, Ehringhaus S, Rao SR, Moy B, Feibelmann S, Goold SD. Institutional academic industry relationships. JAMA. 2007;298(15):1779-1786.
6. Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training. A thematic review. J Gen Intern Med. 2005;20(8):777-786.
7. Fitz M, Homna D, Reddy S, Griffith C, Baker E, et al. The hidden curriculum: medical students' changing opinions toward the pharmaceutical industry. Acad Med. 2007;82:S1-S3.
8. Bellin M, McCarthy S, Drevlow L, Pierach C. Medical students' exposure to pharmaceutical industry marketing: a survey at one U.S. medical school. Acad Med. 2004;79:1041-1045.
9. Hyman P, Hochman M, Shaw J, Steinman M. Attitudes of preclinical and clinical medical students toward interactions with the pharmaceutical industry. Acad Med. 2007;82:94-99.
10. Fein E, Vermillion M, Uijtdehaag S. Pre-clinical medical students' exposure to and attitudes toward pharmaceutical industry marketing. Med Educ. Online 2007;12. Available at: http://www.med-ed-online.net/index.php/meo/ article/viewArticle/4465.
11. Sierles FS, Brodkey AC, Cleary LM, McCurdy FA, Mintz M, Frank J, Lynn DJ, Chao J, Morgenstern BZ, Shore W, Woodard JL. Medical students' exposure to and attitudes about drug company interactions: a national survey. JAMA. 2005;294(9):1034-1042.
12. Soyk C, Pfefferkorn B, McBride P, Rieselbach R. Medical student exposure to and attitudes about pharmaceutical companies. WMJ. 2010;109(3):142-148.
13. Austad KE, Avorn J, Kesselheim AS. Medical students' exposure to and attitudes about the pharmaceutical industry: a systematic review. PLoS Med. 2011;8(5):e1001037.
14. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283(3):373-380.
15. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988;8:13-20.
16. Sondergaard J, Vach K, Kragstrup J, Andersen M. Impact of pharmaceutical representative visits on GPs' drug preferences. Fam Pract. 2009;26:204-209.
17. Institute of Medicine. Conflict of interest in medical research, education, and practice. Washington, D.C.: National Academies Press; 2009.
18. Association of American Medical Colleges. Industry funding of medical education: report of an AAMC task force. June 2008. Available at: https://members.aamc.org/eweb/upload/ Industry%20Funding%20of%20Medical%20Education.pdf. Accessed 14 Jan 2013.
19. Stanford School of Medicine. New policy on continuing medical education. 19 Aug 2008. Available at: http://med.stanford.edu/coi/documents/deanpizzo- cmeletter.pdf. Accessed 14 Jan 2013.
20. Pharmaceutical Research and Manufacturers of America. PhRMA code on interactions with healthcare professionals. July 2008. Available at: http://www.phrma.org/sites/default/files/369/phrma-marketing-code-2008-1.pdf. Accessed 14 Jan 2013.
21. University of Iowa health care conflict of interests and conflict of commitment policy regarding interactions with industry. 20 January 2009. Available at: http://www.healthcare.uiowa.edu/cme/planning/documents/ FinalCOIPolicy.pdf. Accessed 14 Jan 2013.
22. Fugh-Berman A, Brown SR, Trippett R, Bell AM, Clark P, Fleg A, Siwek J. Closing the door on pharma? A national survey of family medicine residencies regarding industry interactions. Acad Med. 2011;86(5):649-654.
23. Kao AC, Braddock C 3rd, Clay M, Elliott D, Epstein SK, Filstead W, Hotze T, May W, Reenan J. Effect of educational interventions and medical school policies on medical students' attitudes toward pharmaceutical marketing practices: a multi-institutional study. Acad Med. 2011;86(11):1454-1462.
24. Weissman JS, Betancourt J, Campbell EG, Park ER, Kim M, Clarridge B, Blumenthal D, Lee KC, Maina AW. Resident physicians' preparedness to provide cross-cultural care. JAMA. 2005;294(9):1058-1067.
25. US News. Best medical schools: research. 2011. Available at: http://grad-schools.usnews.rankingsandreviews.com/best-graduate-schools/ top-medical-schools/research-rankings. Accessed 14 Jan 2013.
26. American Association for Public Opinion Research. Standard definitions: final dispositions of case codes and outcome rates for surveys. 2009. Available at: http://www.aapor.org/AM/Template.cfm?Section=Standard- Definitions1&Template=/CM/ContentDisplay.cfm&ContentID=1814. Accessed 14 Jan 2013.
27. Johnson TP, Wislar JS. Response rates and nonresponse errors in surveys. JAMA. 2012;307(17):1805-1806.
28. Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med. 2011;8(4):e1000431.
29. Mullan F, Chen C, Petterson S, Kolsky G, Spagnola M. The social mission of medical education: ranking the schools. Ann Intern Med. 2010;152(12):804-811.
30. Chimonas S, Brennan TA, Rothman DJ. Physicians and drug representatives: exploring the dynamics of the relationship. J Gen Intern Med. 2007;22(2):184-190.
31. Chren M-M, Landefeld CS. Physicians' behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994;271:684-689.
32. Manchanda P, Honka E. The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. Yale J Health Policy Law Ethics. 2005;5:785-812.
33. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982;73(1):4-8.
34. Agrawal S, Saluja I, Kaczorowski J. A prospective before-and-after trial of an educational intervention about pharmaceutical marketing. Acad Med. 2004;79:1046-1050.
35. Austad KE, Kesselheim AS. Conflict of interest disclosure in early medical education: should medical students stay in the dark? JAMA. 2011;306:991-992.
36. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol. 1997;50(10):1129-1136.